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Special Article
Since noncommunicable diseases (NCDs) are generally controllable rather than curable, more emphasis is placed on prevention than 
on treatment. For the early detection of diseases, primary care physicians (PCPs), as well as general practitioners and family physicians, 
should interpret screening results accurately and provide screenees with appropriate information about prevention and treatment, in-
cluding potential harms. The concept of quaternary prevention (QP), which was introduced by Jamoulle and Roland in 1995, has been 
applied to screening results. This article summarizes situations that PCPs encounter during screening tests according to the concept of 
QP, and suggests measures to face such situations. It is suggested that screening tests be customized to fit individual characteristics 
instead of being performed based on general guidelines. Since screening tests should not be carried out in some circumstances, fur-
ther studies based on the concept of prevention levels proposed by Jamoulle and Roland are required for the development of strate-
gies to prevent NCDs, including cancers. Thus, applying the concept of QP helps PCPs gain better insights into screening tests aimed at 
preventing NCDs and also helps improve the doctor-patient relationship by helping screenees understand medical uncertainties.
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INTRODUCTION 
In the framework of the epidemiological transition first de-
scribed by Omran in 1971 [1], the present period is defined as 
“the age of degenerative and man-made diseases.” In other 
words, the major diseases managed by primary care physi-
pISSN 1975-8375 eISSN 2233-4521 
cians (PCPs), as well as general practitioners and family physi-
cians worldwide, are noncommunicable diseases (NCDs), such 
as cardiovascular diseases, diabetes mellitus, and cancer [2]. 
NCDs are generally controllable rather than curable [3,4], so 
more emphasis is placed on continuity of care with the provi-
sion of adequate information to patients [5] and the preven-
tion of adverse drug events [6] than on curative treatment.
PCPs expend considerable effort in preventing NCDs by 
modifying environments likely to cause diseases, improving 
lifestyles to facilitate health promotion [7], providing vaccina-
tions, and conducting screening tests for the early detection 
of diseases [8]. Based on the definition of medical screening 
proposed by Wald [9], the major aim of screening is to identify 
individuals at a meaningful level of risk for a specific disorder. 
However, it is sometimes uncertain whether screening can 
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prevent early deaths by detecting certain diseases in their ear-
ly stages [10,11]. In addition, screening tests are not applied to 
symptomatic patients, but to people who feel healthy [8,12], 
such that PCPs should consider harms, such as overtreatment 
caused by overdiagnosis and false-positive results and psy-
chological stress, including the anxiety placed on screenees 
[13-16]. Moreover, ethical issues have been raised regarding 
screening tests that are performed without adequate evidence 
of their merits and demerits [17,18]. Although recent publica-
tions on screening tests have suggested tailored screening 
tests that consider the values and preferences of screenees 
[13,19,20], the aim of this paper was to develop action plans 
for PCPs in responding to guide their responses to the results 
of screening tests. 
BODY
PCPs choose appropriate screening tests for each healthy in-
dividual, and must interpret the results correctly. In order to 
accomplish this, analytical frameworks for screening should 
be established. Numerous frameworks have been introduced 
according to the natural history of various diseases [8,21,22], 
based on the concept of secondary prevention introduced by 
Leavell and Clark in 1940s [23]. A troublesome situation for 
PCPs is when a screening test gives a negative result, and the 
PCP has to reduce the harms of screening, but the screenee 
does not accept this course of action [16]. The prevention con-
cept defined by Leavell and Clark does not address such situa-
tions [24-26]. In contrast, the concept of quaternary preven-
tion (QP), introduced by Jamoulle and Roland in 1995 [27], 
points out that all medical processes are not inherently benefi-
cial to the patient and therefore embraces efforts to reduce 
harmful impacts on healthy individuals who visit PCPs. They 
defined QP as ‘the actions taken to identify a patient or a pop-
ulation at risk of overmedicalization, to protect them from in-
vasive medical interventions, and to provide methods of care 
that are both scientifically and ethically acceptable’ [27-29]. 
Among four domains of prevention defined based on interre-
lationships between patients and doctors, the quaternary level 
of prevention refers to a situation in which a patient feels ill 
but the doctor concludes that no disease is present (Figure 1) 
[26-28]. Therefore, this article summarizes situations that PCPs 
encounter during screening tests according to the concept of 
QP, and suggests measures to face such situations.
 
Situations Encountered by Primary Care 
Physicians and Changes in Prevention Levels
Jamoulle and Roland [27] introduced four levels of preven-
tion corresponding to different types of interactions between 
medical service consumers and providers, centered on the 
lifelong timeline from birth to death. Whereas the prevention 
levels of Leavell and Clark were proposed according to the 
natural history of diseases with particularly syphilis natural 
story [24], the prevention levels articulated by Jamoulle and 
Roland are based on the relationships between patients and 
providers and emphasize variations across the life cycle of 
consumers [29] (Figure 1, Table 1). In particular, the fourth lev-
el of QP occurs when a PCP decides that no disease is present 
although the patient feels ill [26-28]. The introduction of this 
fourth level corresponded very well with real-world develop-
Figure 1. Fuzzy limits in provider (disease) vs. patient (illness) 








Table 1. Differential aspects of prevention levels between 
Leavell and Clark [23] vs. Jamoulle and Roland [27]
Aspects Leavell and Clark Jamoulle and Roland
Based on Natural history of a target 
   disease 
Lifelong timeline
Diseases that fit 
   the model well
(Infectious) diseases Ongoing illness
Shape of 
   paradigm
Epidemic triangle Circular wheel
Mechanism Host-agent-environment 
   equilibrium
Gene-socio-environmental 
   interactions
Underlying 
   condition 
Behaviors or habits Susceptible genes, culture, 
   or resources
Main targets Infectious organisms Modifiable lifestyles, self- 
   care, and health beliefs
Related 
   environments
Socioeconomic status, 
   occupational conditions
Socioeconomic status, 
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ments towards the control of overmedicalization [29]. More-
over, as shown in Figure 1, the boundary between the pres-
ence and absence of disease are fuzzy, and the accuracy of 
such boundaries is subject to discussion. In other words, 
vagueness is the rule in health care [30] because the illness 
behavior of patients is conditioned by health beliefs [31], and 
boundaries between disease and illness are not always clear 
[32], particularly in mental health [33]. Thus, prevention levels 
may vary according to the treatment offered by providers, the 
demands for medical services by consumers, and variations 
across the life course, even for the same consumer. 
In order to understand how prevention levels change ac-
cording to consumers’ situations and their timelines, scenarios 
that PCPs may encounter during screening for breast cancer 
are listed in Table 2. Since a human being begins life from 
birth, the first level is the primary level, which includes genetic 
factors. The level of prevention varies widely according to the 
purposes of patients’ visits and the potential for several con-
current medical conditions to be present within one person 
[34] as multi-morbidity is increasingly the norm in the man-
agement of chronic diseases in general practice [35]. 
Primary Care Physicians’ Action Plans According 
to Screening Results
Despite serious doubts about the accuracy and efficiency of 
screening [10], and some confusion about the recommenda-
tions [36,37], cancers including breast, uterine cervix, colon, 
and stomach are regularly screened for in the normal-risk pop-
ulation, according to cancer screening guidelines [38]. How a 
PCP should interpret and manage screening results according 
to the prevention level of screenees is organized in Table 3.
Preferentially, screening test results are divided into true or 
false, as determined by the provider who decides the preven-
tion level of the consumer [39]. If the results come out as true 
positive (TP) or true negative (TN) and the consumer accepts 
the decision of the provider (TP1, TN1), medical judgements 
and shared decision-making are not hard. However, when the 
decisions made by the provider and the patient are different 
[40], even if the results come out as true negative (TN2), the 
patient-doctor relationship may encounter difficulties [41]. 
Therefore, while implementing efforts to prevent overtreat-
ment and informing consumers of the possibility of screening 
errors, PCPs should try to establish and maintain trust.
For false positive (FP) and false negative (FN) results, when 
the consumer and provider agree on the results (TP1, FN1), they 
should make efforts towards “sharing decision-making” [42]. 
However, in situations when they decide differently (TP2, FN2), 
the patient-doctor relationship is likely to encounter difficulties 
[17]. In the case of FN2, PCPs consider to shorten screening in-
tervals. In the case of TN2, PCPs should make their best efforts 
to prevent overdiagnosis and overtreatment with unnecessary 
screening tests [43]. In particular, stopping the screening pro-
cess may be an important decision for many older adults [44].
Table 2. Some hypothetical scenarios experienced by a primary care physician (PCP) regarding a screening mammography (SM) 
and the shifting levels of prevention suggested by Jamoulle and Roland [27]
Types1 Hypothetical scenarios Shifting levels of activities Hypothetical next paths
12 A prompt treatment for a painful breast mass III ->  III ->  I, III, or death
23 Prompt management of a mass found by the SM as recommended by the PCP I ->  II ->  III ->  I, III, or death
34 Reassurance with watchful waiting and avoiding overtreatment of a benign lesion 
   found by the SM as recommended by the PCP
I ->  II ->  IV  ->  I 
45 Prompt treatment of an evidently dangerous mass found by chance I ->  II ->  III ->  I, III, or death
56 Valid evaluation for a palpable mass found by chance, such as an incidentaloma II ->  IV  ->  I, III, or death
1Complexity arises from the interaction of doctor and patient knowledge in different situations; In each case, poor communication skills, inattention, and/or lack 
of process control could make the patient remain in category IV; that is, insecure and worried.
2The patient knows he/she has a problem (III) and the doctor accepts and provides care for it (III); The problem resolves (I), remains chronic (III), or the patient dies.
3The patient is asymptomatic and healthy (I), and undergoes screening (II); The doctor finds and provides care for a disease (III); The patient recovers (I), the 
problem remains chronic (III), or the patient dies.
4The patient is asymptomatic and healthy (I), and undergoes screening (II); The problem found is benign and the problem resolves (I), or the patient does not 
believe it has resolved and remains sick or worried (IV); Reassurance and good communication allow the patient to feel healthy (I).
5The patient is asymptomatic and healthy (I), and undergoes screening (II); Early diagnosis is made by chance (II); the doctor finds and provides care for a disease 
(III); The patient recovers (I), the problem remains chronic (III), or the patient dies.
6The patient has an ongoing health problem (III); The doctor unexpectedly finds a new problem unknown to the patient; that is, an incidentaloma (II) that induces 
anxiety in the patient (IV); Either the problem was in fact trivial and after explanation the patient does not worry anymore (I), or the patient becomes severely ill 
and is cared for (III); The patient recovers (I), the problem remains chronic (III), or the patient dies. 
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CONCLUSION AND SUGGESTION
The previous discussion has summarized how the prevention 
levels proposed by Jamoulle and Roland may vary according to 
the demands of consumers, using the example of screening 
tests for cancer. Additionally, suggestions have been made for 
how PCPs should interpret and manage screening test results.
This simplification of the process improves PCPs’ insights into 
screening tests for preventing chronic diseases. It also under-
scores the depth of the complexity that PCPs must deal with 
[40], as well as the necessity of training future PCPs in commu-
nication skills and appropriate shared decision-making [45].
This framework also contributes to improvements in the 
doctor-patient relationship by facilitating the consumer’s un-
derstanding of medical uncertainty [45]. In addition, establish-
ing proper strategies for screening tests that are carried out in 
primary care contexts through the implementation of QP is 
supportive of population-health approaches [46].
Nonetheless, immediately prior to the final diagnosis of a 
disease, providers should avoid binary constraints in shared 
decision-making, even if consumers demand a more certain 
decision. Instead, PCPs should provide accurate information 
on the characteristics of NCDs and the advantages and disad-
vantages of screening tests using decision aids [18,46,47]. 
Currently, the concept of screening tests has moved away 
from the terms of compliance and adherence and toward the 
concept of cooperation and participation or empowerment, 
which refers to how consumers understand suggested screen-
ing tests and make decisions based on their values [48]. There-
fore, it is increasingly suggested that screening tests should be 
customized to fit individual characteristics instead of being 
based on guidelines [19,20]. 
As indicated by the fact that the epidemic of thyroid cancer 
in South Korea resulted from unnecessary screening [49], 
Table 3. Action plans for primary care physicians (PCPs) according to the result of a screening or diagnostic test by levels of pre-
vention
Level Consumer Provider








Action plan of the PCP
I Feel well Rule out no illness FP1 Delivery of bad news
Explanation of the limits of medicine
Shared decision-making process for the next steps
Partnership in the management of the disease
TN1 Explain the concept of negative results as well 
    as false negatives and the uncertainty of the 
doctor
Explain how to remain healthy
II Feel well Rule out illness TP2 Delivery of bad news in a different relationship 
   with the patient
Sharing the limits of screening test 
Conducting tests for the final diagnosis
FN2 Discuss the limit of screening test
Encourage and monitor regular screening tests 
   if appropriate
Repeat the screening within the next interval 
   if appropriate
III Feel ill Rule out disease TP1 Patient and doctor agree on the disease discovered
Providing proper treatment
FN1 Conduct new tests for the final diagnosis 
Prevent and identify adverse events
 If the test is negative, no treatment actions  
   are necessary
If further testing is useless, introduce palliative 
   care
IV Feel ill Rule out no disease FP2 Sharing the limits of the test asked under pressure 
   of the patient
Discussing further testing while protecting against 
   overscreening
TN2 Empowering with protection against over- 
   treatment 
In-depth communication about the subjective 
   feeling of illness 
Explain doctors’ ignorance regarding 
   inexplicable human suffering
Be careful about false negatives (missed 
   diagnosis)
Master your own anxiety, the following 
    standard guidelines about emotionally de-
manding patients
Use time and trust to maintain a healthy 
   doctor-patient relationship
FP, false positive; TN, true negative; TP, true positive; FN, false negative; 1, situation that patient and doctor agree; 2, situation that patient and doctor disgree. 
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screening tests should not be done in some circumstances 
[39]. Further studies based on the concept of prevention levels 
proposed by Jamoulle and Roland are required to develop 
strategies to prevent NCDs, including cancers. In addition, ex-
panded studies on developing strategies for patients with 
multiple morbidities in primary care clinics are necessary.
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